BridgeBio is substantially boosted the course of an novel solution for ATTR-CM, employing the investigational drug. Initial trial results suggests significant benefits for those diagnosed by a debilitating condition. The emphasis underscores BridgeBio's focus to managing critical patient requirements in this heart space. Attruby: BridgeBio's Novel